NCT06288893Not yet recruiting
SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SHEN211 Tablets in the Treatment of Patients With Mild and Moderate Novel Coronavirus Infection
JKT Biopharma Co., Ltd.Phase 2ClinicalTrials.govdrug
Study focus
- Disease/Condition
- COVID-19
- Drug/Device/Intervention
- SHEN211 Tablets
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- JKT Biopharma Co., Ltd.
- Location
- Shenzhen, China
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Apr 01, 2024
- End date
- Jan 01, 2025
- Enrollment
- 30 participants
Primary outcome
Change from baseline in SARS-CoV-2 viral load at each time point
Summary
Randomized, double-blind, placebo-controlled, multicenter phase II clinical study of SHEN211
 tablets
ICD-10 classifications
COVID-19, virus identifiedCOVID-19, virus not identifiedCoronavirus infection, unspecified siteViral infection, unspecifiedRift Valley fever
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06288893
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06288893 through Pure Global AI's free database. This Phase 2 trial is sponsored by JKT Biopharma Co., Ltd. and is currently Not yet recruiting. The study focuses on COVID-19. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.